Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy

Haemophilia. 2023 Nov;29(6):1653-1655. doi: 10.1111/hae.14854. Epub 2023 Sep 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Bispecific* / pharmacology
  • Antibodies, Bispecific* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Factor VIII / therapeutic use
  • Hemophilia A* / drug therapy
  • Humans

Substances

  • emicizumab
  • Factor VIII
  • Antibodies, Bispecific
  • Antibodies, Monoclonal, Humanized